Yashika Parashar, Aya Awwad, Soahum Bagchi, Brian Claggett, Saman Asad Siddiqui, Ajari Winifred Ogheneochuko, Christie M Ballantyne, Christopher deFilippi
{"title":"A Meta-Analysis and Systematic Review of Cardiac Troponin I vs T in Community Dwelling Adults: Is Specificity at Risk?","authors":"Yashika Parashar, Aya Awwad, Soahum Bagchi, Brian Claggett, Saman Asad Siddiqui, Ajari Winifred Ogheneochuko, Christie M Ballantyne, Christopher deFilippi","doi":"10.1093/clinchem/hvaf023","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cardiac troponin I and T measured by high-sensitivity assays (hs-cTn) are detectable in most ambulatory adults. Hs-cTnI and T may perform differently for prediction of cardiovascular (CV) events. In adults with myopathies and advanced age, hs-cTnT can lose CV specificity. We undertook a meta-analysis of ambulatory studies measuring hs-cTn to determine whether hs-cTnI is a superior predictor of CV outcomes.</p><p><strong>Methods: </strong>Articles evaluating hs-cTnI or T for incident heart failure (HF), myocardial infarction (MI), CV, and all-cause death in ambulatory adults were screened. Adjusted HRs were extracted standardized as hs-cTn tertile 3 vs 1. Pooled effects were calculated, and heterogeneity assessed. Predefined subgroup analyses for hs-cTnI vs T included age and prevalent CV disease.</p><p><strong>Results: </strong>A total of 5499 studies were screened and 54 met inclusion criteria with up to 277 498 participants followed for 8.1 ± 4.5 years. Pooled estimates for HF, MI, CV, and all-cause death were reported as 2.30 [95% confidence interval (CI) 2.04, 2.60], 1.64 (95%CI 1.47, 1.86), 2.07 (95%CI 1.82, 2.35), and 1.66 (95%CI 1.51, 1.83). No differences in HRs for subgroups based on hs-cTnI vs hs-cTnT (except all-cause death), age, or prevalent CV disease were observed. Heterogeneity between studies was high with an I2 > 60% for all endpoints for both hs-cTn assays. In a sensitivity analysis of studies measuring both hs-cTnI and T there was also no differences for the prediction of any CV endpoint.</p><p><strong>Conclusions: </strong>Hs-cTnI and T prediction of multiple CV endpoints are not significantly different irrespective of age and pre-existing CV disease in ambulatory adults.</p>","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":" ","pages":""},"PeriodicalIF":7.1000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/clinchem/hvaf023","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Cardiac troponin I and T measured by high-sensitivity assays (hs-cTn) are detectable in most ambulatory adults. Hs-cTnI and T may perform differently for prediction of cardiovascular (CV) events. In adults with myopathies and advanced age, hs-cTnT can lose CV specificity. We undertook a meta-analysis of ambulatory studies measuring hs-cTn to determine whether hs-cTnI is a superior predictor of CV outcomes.
Methods: Articles evaluating hs-cTnI or T for incident heart failure (HF), myocardial infarction (MI), CV, and all-cause death in ambulatory adults were screened. Adjusted HRs were extracted standardized as hs-cTn tertile 3 vs 1. Pooled effects were calculated, and heterogeneity assessed. Predefined subgroup analyses for hs-cTnI vs T included age and prevalent CV disease.
Results: A total of 5499 studies were screened and 54 met inclusion criteria with up to 277 498 participants followed for 8.1 ± 4.5 years. Pooled estimates for HF, MI, CV, and all-cause death were reported as 2.30 [95% confidence interval (CI) 2.04, 2.60], 1.64 (95%CI 1.47, 1.86), 2.07 (95%CI 1.82, 2.35), and 1.66 (95%CI 1.51, 1.83). No differences in HRs for subgroups based on hs-cTnI vs hs-cTnT (except all-cause death), age, or prevalent CV disease were observed. Heterogeneity between studies was high with an I2 > 60% for all endpoints for both hs-cTn assays. In a sensitivity analysis of studies measuring both hs-cTnI and T there was also no differences for the prediction of any CV endpoint.
Conclusions: Hs-cTnI and T prediction of multiple CV endpoints are not significantly different irrespective of age and pre-existing CV disease in ambulatory adults.
期刊介绍:
Clinical Chemistry is a peer-reviewed scientific journal that is the premier publication for the science and practice of clinical laboratory medicine. It was established in 1955 and is associated with the Association for Diagnostics & Laboratory Medicine (ADLM).
The journal focuses on laboratory diagnosis and management of patients, and has expanded to include other clinical laboratory disciplines such as genomics, hematology, microbiology, and toxicology. It also publishes articles relevant to clinical specialties including cardiology, endocrinology, gastroenterology, genetics, immunology, infectious diseases, maternal-fetal medicine, neurology, nutrition, oncology, and pediatrics.
In addition to original research, editorials, and reviews, Clinical Chemistry features recurring sections such as clinical case studies, perspectives, podcasts, and Q&A articles. It has the highest impact factor among journals of clinical chemistry, laboratory medicine, pathology, analytical chemistry, transfusion medicine, and clinical microbiology.
The journal is indexed in databases such as MEDLINE and Web of Science.